阿替洛尔/氯噻酮(Atenolol/Chlorthalidone) - 药物靶点：NCC x β1-adrenergic receptor_在研适应症：高血压_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Tenoretic

靶点

NCC x β1-adrenergic receptor

作用机制

NCC抑制剂(噻嗪类敏感氯化钠协同转运蛋白抑制剂)、β1-adrenergic receptor拮抗剂(β1-肾上腺素能受体拮抗剂)

治疗领域

心血管疾病

在研适应症

高血压

非在研适应症-

原研机构

AstraZeneca PLC

在研机构

安成国际药业股份有限公司

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (1984-06-08),

高血压

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C28H33ClN4O7S

InChIKeyGEGCOFDJWXJACT-UHFFFAOYSA-N

CAS号73677-19-7

关联

100 项与阿替洛尔/氯噻酮相关的临床结果

登录后查看更多信息

100 项与阿替洛尔/氯噻酮相关的转化医学

登录后查看更多信息

100 项与阿替洛尔/氯噻酮相关的专利（医药）

登录后查看更多信息

4

项与阿替洛尔/氯噻酮相关的文献（医药）

1990-07-01·Klinicheskaia meditsina

Effektivnost' dlitel'noĭ antigipertenzivnoĭ terapii tenorikom--kombinirovannym preparatom prolongirovannogo deĭstviia.

Article

作者: Grigor'ev, Iu V ; Sinopal'nikov, A I ; Ivashkin, V T

1990-03-01·African journal of medicine and medical sciences

Assessment of a fixed-dosage combination of atenolol and chlorthalidone (Tenoretic) in hypertensive Nigerians.

Article

作者: Walker, O ; Falase, A O ; Salako, L A ; Aderounmu, A F

The antihypertensive effect of a fixed dosage combination of the cardioselective beta-adrenoceptor blocker, atenolol, and the oral thiazide-like diuretic, chlorthalidone (Tenoretic) was studied in 24 hypertensive Nigerians in a double-blind, cross-over comparison with three other treatments. These were atenolol alone, 100 mg daily, chlorthalidone alone, 25 mg daily, and atenolol (100 mg) plus chlorthalidone (25 mg) daily taken as separate formulations. Tenoretic was taken as a once-daily tablet containing 100 mg atenolol plus 25 mg chlorthalidone. The order of administration of the drugs was randomized. Each drug was taken for 4 weeks. The results showed that atenolol and chlorthalidone lowered blood pressure to the same extent. Combination of the two drugs whether taken separately or in fixed-dosage combination was better than either product singly. The drugs were well tolerated.

1988-11-01·Southern Medical Journal4区 · 医学

A Double-Blind Comparison

4区 · 医学

Article

作者: Urban, P L ; Schwartz, K M ; Curry, R C

In a randomized, double-blind, parallel-group study of 31 patients with mild to moderate hypertension, we compared a placebo regimen with a regimen of atenolol and chlorthalidone (Tenoretic). The study, which lasted seven weeks, began with a single-blind two-week placebo lead-in period, followed by a four-week double-blind treatment phase, and concluded with a one-week single-blind placebo washout period. Of 24 patients included in the analysis of efficacy, seven received one Tenoretic 50 tablet per day (atenolol, 50 mg; chlorthalidone, 25 mg), nine received one Tenoretic 100 tablet per day (atenolol, 100 mg; chlorthalidone, 25 mg), and eight received placebo. Supine systolic/diastolic blood pressure (mean +/- SD) decreased from 154 +/- 15.2/102 +/- 4.6 mm Hg during the baseline period to 128 +/- 8.5/85 +/- 4.0 mm Hg during treatment in the group receiving Tenoretic 100, from 153 +/- 12.6/104 +/- 5.4 mm Hg to 137 +/- 4.5/91 +/- 4.4 mm Hg in the group receiving Tenoretic 50, and from 150 +/- 11.9/101 +/- 1.6 mm Hg to 145 +/- 11.6/93 +/- 5.1 mm Hg in the group receiving placebo. Reductions in systolic and diastolic blood pressures in the active treatment groups were significantly greater than the pressure reductions in the group receiving placebo (P less than .05 to .1). The combination of atenolol and chlorthalidone was well tolerated, and in no case was treatment discontinued because of side effects. This study showed that one tablet per day of either Tenoretic 50 or Tenoretic 100 is effective and well tolerated in the treatment of mild to moderate hypertension.

2

项与阿替洛尔/氯噻酮相关的新闻（医药）

2020-03-02

·BioPortfolio

AstraZeneca completes divestment agreement with Atnahs Pharma for established hypertension medicines

AstraZeneca today announced that it has completed the previously communicated agreement with Atnahs Pharma (Atnahs) to divest its global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination).

合作

2020-01-27

·Endpoints

After a brief break, AstraZeneca is back at divesting — handing off hypertension meds for $350M

On the same day that it’s getting back an experimental IL-23 drug from AbbVie and Allergan’s pre-merger divestiture exercise, AstraZeneca has engineered a sale of its own. The pharma giant is collecting $350 million from Atnahs Pharma for global commercial rights to a suite of five off-patent hypertension drugs: Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination). Together, they generated sales of $132 million in 2018 in the markets covered by the deal, which excluded the US, India and Japan, according to AstraZeneca. The US and India rights were already divested, while the drugmaker is retaining rights to market in Japan. Atnahs, a specialist in “mature branded meds” with offices in the UK, Denmark, UAE, Australia and India, is also promising sales-contingent payments up to $40 million in the next two years. “This transaction supports our strategy to realise value from our portfolio of non-core mature brands, enabling further investment in new medicines,” Ruud Dobber, EVP of the BioPharmaceuticals business unit, said in a statement. During a transition period, AstraZeneca will continue to manufacture and supply the drugs to Atnahs. Inderal, Tenormin and Tenoretic are beta-blockers, while Zestril and Zestoretic both contain the same angiotensin-converting enzyme (ICE) inhibitor. In late 2018 AstraZeneca inked a flurry of deals to prune its portfolio and focus on the new flagship products, notably cancer drugs such as Lynparza, Imfinzi, Tagrisso and Calquence. A few months later in 2019, CEO Pascal Soriot executed a complete revamp of the company structure, dissolving the MedImmune subsidiary, enshrining the oncology franchise and refashioning everything else along that line. Previous divestitures have seen AstraZeneca let go of Nexium and Losec for stomach problems, anti-inflammatory drug Vimovo , RSV drug Synagis , as well as the respiratory therapies Alvesco, Omnaris and Zetonna.

并购

100 项与阿替洛尔/氯噻酮相关的药物交易

登录后查看更多信息